• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Alpha-Gal Syndrome as a Potential Cause of Allergic Transfusion Reactions

September 9, 2026

Alpha-Gal syndrome (AGS) is an acquired allergic reaction caused by IgE antibodies against galactose-α-1-3-galactose (alpha-Gal), a carbohydrate expressed by most mammals but not humans. Bites from certain tick species, Amblyomma americanum (lone star tick) in the U.S., can stimulate the production of these antibodies. Many alpha-Gal antibodies cross-react with the human blood group B-antigen, and allergic transfusion reactions (ATRs) have been reported in blood type O recipients receiving B or AB blood products, leading researchers to hypothesize that anti-alpha-Gal IgE-mediated ATRs may occur (termed transfusion-related alpha-Gal syndrome [TRAGS]). To test whether individuals with type O individuals receiving B or AB blood products have higher ATR risk, researchers retrospectively analyzed over 500,000 platelet and plasma transfusions (0.3% ATR rate) at 40 sites in five countries where rates of AGS had been calculated in 2024. In the nine U.S. sites categorized with high AGS (11 to 87 AGS cases/million population/year), more ATRs occurred in type O recipients who received B or AB platelets or plasma compared with type O recipients who received type O platelets or plasma (overall risk ratio, 3.93; 95% C.I., 2.96 to 5.21; p <0.001). No difference in ATR risk was observed between type O recipients who received B or AB products vs. those who received type O products in areas with fewer cases of AGS (0 to <11 AGS cases/million/population/year).  These data suggest TRAGS could be occurring.  No evidence of TRAGS was observed outside of the U.S. More research is needed to better understand the association between anti-alpha-Gal IgE and TRAGS and whether individuals with group A blood are affected.

References:

  1. Kaufman RM, Hoen AG, Khan J, Knudson CM, et al. Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome. JAMA Intern Med. 2026 Aug 24:e263983. doi: 10.1001/jamainternmed.2026.3983. Epub ahead of print. PMID: 42636004; PMCID: PMC13504484.
  2. Hollenhorst MA, Anderson JR, Dzik W. Ticks and Transfusion at the Crossroads—Alpha-Gal Syndrome. JAMA Intern Med. Published online August 24, 2026. doi:10.1001/jamainternmed.2026.3993

Filed Under

  • Adverse Events (non-infectious)
  • News

Recommended

  • Increased Transfusion Volume May Benefit Children with Severe Anemia in Africa

  • Extended Trial Confirms that Frequent Donors Give More Blood but Are More Likely to be Iron Deficient

  • Gene Therapy Phase 3 Study Results for Hemophilia B

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Increased Mortality in Trauma Patients with Non-identical ABO Transfusions

  • Intravenous Iron for Anemia before Elective Cardiac Surgery

  • Hemoglobin Levels and Risk of Mortality

  • Alpha-Gal Syndrome as a Potential Cause of Allergic Transfusion Reactions

    Question of the Day

    Copyright © 2026 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley